Peng Yue
Company: ReviR Therapeutics
Job title: Co-Founder & Chief Executive Officer
Bio:
A computational biologist with a strong interest in improving human health through engineering drug discovery process.
Over 18 years of hands-on biotech experience specializing in genomics, oncology, virology, fibrosis, immunology and inflammation (GeneLogic, Genentech, Gilead, 23andme).
Expertise in multivariate regression, machine learning, and bioinformatics analysis of large scale genomic data including microarray – expression arrays, exon array and SNP array, next generation sequencing (NGS) – RNA-seq, Exome-seq, ChIP-seq, and proteomics.
Seminars:
Accelerating Splicing Modulation Therapies for Neurodegeneration with the VoyagR Platform 11:00 am
• Finalizing development of a lead candidate targeting HTT and PMS1 splicing with support from CIRM for IND-enabling studies in Huntington’s disease to accelerate clinical readiness and unlock therapeutic potential • Accelerating preclinical development with refined single-molecule chemistry and new functional datasets to enhance compound validation and improve translational confidence in ReviR’s lead asset •…Read more
day: Conference Day One
Panel Discussion Increasing Chemical Diversity in RNA-Targeted Splice Modulator Small Molecules to Expand the Target Space & Address Previously Undruggable Diseases 1:00 pm
• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas • What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space • Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic…Read more
day: Conference Day One
Panel Discussion: Building Strategic Collaborations & Investment Pathways to Accelerate RNA-Targeted Drug Discovery Across Biotech & Pharma 8:45 am
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics • How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines • How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets…Read more
day: Conference Day Two